The chief medical officer of Gain Therapeutics discusses the challenges that are unaddressed with currently available treatments for Parkinson, and how investigational treatments like GT-02287 might address those needs. [WATCH TIME: 3 minutes]
Jonas Hannestad, MD, PhD
Advertisement
Chief Medical Officer, Gain Therapeutics
Articles by Jonas Hannestad, MD, PhD
The chief medical officer of Gain Therapeutics discusses GT-02287, a promising treatment for Parkinson that has shown strong safety and tolerability in an ongoing phase 1 trial. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Phase 1b Interim Data on GT-02287 in Parkinson Disease: Jonas Hannestad, MD, PhDPublished: October 5th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Building the Next Era of ALS Clinical Research and Trials
2
Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD
3
Optimizing Treatment Selection and Moving Beyond the Plateau
4
Understanding Access to Rehabilitation for Stroke Survivors: Talya Fleming, MD
5
